Wall Street brokerages expect Emergent Biosolutions Inc (NYSE:EBS) to report earnings per share of $0.51 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Emergent Biosolutions’ earnings, with estimates ranging from $0.38 to $0.58. Emergent Biosolutions reported earnings per share of $0.73 in the same quarter last year, which would indicate a negative year over year growth rate of 30.1%. The business is expected to issue its next quarterly earnings report on Thursday, November 1st.
According to Zacks, analysts expect that Emergent Biosolutions will report full-year earnings of $2.37 per share for the current year, with EPS estimates ranging from $2.15 to $2.47. For the next financial year, analysts anticipate that the company will report earnings of $3.25 per share, with EPS estimates ranging from $2.25 to $4.70. Zacks’ EPS calculations are an average based on a survey of research analysts that follow Emergent Biosolutions.
Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported $1.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.19. The business had revenue of $220.20 million for the quarter, compared to analysts’ expectations of $208.94 million. Emergent Biosolutions had a return on equity of 15.09% and a net margin of 16.55%. The firm’s quarterly revenue was up 118.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.13 EPS.
Several research firms have weighed in on EBS. Wells Fargo & Co set a $65.00 price target on Emergent Biosolutions and gave the company a “hold” rating in a report on Wednesday, August 29th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Emergent Biosolutions in a report on Thursday, June 14th. Argus began coverage on Emergent Biosolutions in a report on Wednesday, June 13th. They issued a “buy” rating and a $62.00 price target on the stock. Cowen reaffirmed a “hold” rating and issued a $49.00 price target on shares of Emergent Biosolutions in a report on Wednesday, August 29th. Finally, Chardan Capital raised their price target on Emergent Biosolutions from $53.00 to $57.00 and gave the company a “buy” rating in a report on Friday, August 3rd. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $59.88.
Shares of NYSE:EBS traded down $1.27 on Wednesday, hitting $59.78. The company’s stock had a trading volume of 470,900 shares, compared to its average volume of 329,085. Emergent Biosolutions has a 1 year low of $35.64 and a 1 year high of $64.00. The stock has a market cap of $3.10 billion, a P/E ratio of 32.13, a PEG ratio of 1.31 and a beta of 1.25. The company has a quick ratio of 4.15, a current ratio of 5.59 and a debt-to-equity ratio of 0.01.
In other Emergent Biosolutions news, Director Ronald Richard sold 7,893 shares of the firm’s stock in a transaction dated Tuesday, August 21st. The stock was sold at an average price of $60.02, for a total value of $473,737.86. Following the sale, the director now owns 21,063 shares of the company’s stock, valued at approximately $1,264,201.26. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director George A. Joulwan sold 5,000 shares of the firm’s stock in a transaction dated Monday, June 11th. The shares were sold at an average price of $52.89, for a total value of $264,450.00. Following the completion of the sale, the director now directly owns 30,272 shares in the company, valued at approximately $1,601,086.08. The disclosure for this sale can be found here. In the last ninety days, insiders sold 79,311 shares of company stock worth $4,398,920. Insiders own 13.40% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Stratos Wealth Partners LTD. purchased a new position in shares of Emergent Biosolutions during the 1st quarter valued at about $134,000. PNC Financial Services Group Inc. raised its holdings in shares of Emergent Biosolutions by 108.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,847 shares of the biopharmaceutical company’s stock valued at $149,000 after buying an additional 1,482 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Emergent Biosolutions during the 1st quarter valued at about $171,000. Financial Gravity Wealth Inc. purchased a new position in shares of Emergent Biosolutions during the 1st quarter valued at about $190,000. Finally, Sei Investments Co. raised its holdings in shares of Emergent Biosolutions by 5,992.1% during the 1st quarter. Sei Investments Co. now owns 3,838 shares of the biopharmaceutical company’s stock valued at $202,000 after buying an additional 3,775 shares in the last quarter. 83.01% of the stock is currently owned by institutional investors.
About Emergent Biosolutions
Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.
Featured Story: What is a Fiduciary?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.